Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$11.27M
TTM
Current Assets
$6.687M
Q3 2024
Current Liabilities
$1.946M
Q3 2024
Current Ratio
343.62%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$4.741M
Q3 2024
Cash
Q3 2024
P/E
-0.2282
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019
Selling, General & Admin $3.972M $4.023M $4.398M $1.565M $1.847M
YoY Change -1.28% -8.51% 180.99% -15.28%
% of Gross Profit
Research & Development $4.070M $5.651M $3.459M $1.608M $2.623M
YoY Change -27.98% 63.36% 115.16% -38.71%
% of Gross Profit
Depreciation & Amortization $0.00 $320.00 $1.360K
YoY Change -100.0% -76.47%
% of Gross Profit
Operating Expenses $8.042M $5.651M $3.459M $1.608M $4.471M
YoY Change 42.31% 63.36% 115.16% -64.04%
Operating Profit -$8.042M -$9.674M -$7.857M -$3.173M
YoY Change -16.88% 23.13% 147.63%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019
Interest Expense $247.2K $63.57K $45.61K $197.3K -$250.7K
YoY Change 288.89% 39.37% -76.88% -178.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019
Pretax Income -$7.795M -$9.611M -$7.902M -$3.237M -$4.721M
YoY Change -18.9% 21.62% 144.17% -31.45%
Income Tax $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.795M -$9.611M -$7.902M -$3.237M -$4.721M
YoY Change -18.9% 21.62% 144.17% -31.45%
Net Earnings / Revenue
Basic Earnings Per Share -$2.67 -$0.87 -$2.43 -$1.69
Diluted Earnings Per Share -$2.67 -$0.87 -$948.8K -$388.6K -$566.9K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019
Cash & Short-Term Investments $7.438M $6.241M $10.80M $530.4K $1.992M
YoY Change 19.18% -42.2% 1935.97% -73.37%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $532.1K $690.6K $825.1K $75.05K $73.68K
YoY Change -22.94% -16.31% 999.45% 1.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.979M $6.944M $11.62M $605.5K $2.065M
YoY Change 14.89% -40.26% 1819.88% -70.69%
Property, Plant & Equipment $0.00 $320.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00 $0.00 $320.00
YoY Change -100.0%
Total Assets $7.979M $6.944M $11.62M $605.5K $2.066M
YoY Change
Accounts Payable $866.0K $496.7K $515.3K $104.3K $337.2K
YoY Change 74.36% -3.6% 394.1% -69.07%
Accrued Expenses $757.6K $425.9K $1.002M $133.5K $155.0K
YoY Change 77.87% -57.47% 650.37% -13.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $2.989M $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $556.2K $730.6K
YoY Change -100.0% -23.87%
Total Short-Term Liabilities $1.624M $922.6K $1.517M $3.783M $1.723M
YoY Change 75.98% -39.17% -59.91% 119.61%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $553.2K
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00 $0.00 $553.2K
YoY Change -100.0%
Total Liabilities $1.624M $922.6K $1.517M $3.783M $2.276M
YoY Change 75.98% -39.17% -59.91% 66.23%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019
Basic Shares Outstanding 4.302M shares 1.911M shares
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.5714 Million

About Dermata Therapeutics, Inc.

Dermata Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.

Industry: Pharmaceutical Preparations Peers: AVENUE THERAPEUTICS, INC. Evoke Pharma Inc Grapefruit USA, Inc JOHNSON & JOHNSON NovaBay Pharmaceuticals, Inc. SenesTech, Inc. Stem Holdings, Inc.